Key Points
- DexCom EVP Jereme Sylvain sold 3,638 shares at an average price of $83.27, generating approximately $302,936. The sale reduced his direct ownership by 2.42% and was executed under a pre-arranged Rule 10b5-1 trading plan.
- DexCom’s latest quarterly results exceeded expectations, with earnings of $0.70 per share versus the $0.61 consensus estimate and revenue of $1.31 billion. Revenue increased 13.1% year over year, while net margin was 20.12%.
- Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $88.71. Institutional investors and hedge funds own 97.75% of the company’s shares.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Jereme Sylvain sold 3,638 shares of DexCom stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president directly owned 146,828 shares in the company, valued at $12,226,367.56. This trade represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
DexCom Price Performance
DXCM stock opened at $84.68 on Tuesday. The stock has a market cap of $31.95 billion, a price-to-earnings ratio of 33.47, a P/E/G ratio of 1.39 and a beta of 1.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The company has a 50 day simple moving average of $82.99 and a 200 day simple moving average of $72.88. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59.
DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company's quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the business posted $0.48 earnings per share. Research analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research firms recently commented on DXCM. Stifel Nicolaus set a $95.00 target price on shares of DexCom and gave the stock a "buy" rating in a research report on Friday, July 31st. Barclays restated an "underweight" rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a research note on Tuesday, June 23rd. They set a "buy" rating and a $86.00 price target for the company. Robert W. Baird set a $105.00 price target on shares of DexCom in a report on Friday, July 31st. Finally, UBS Group set a $96.00 price objective on shares of DexCom and gave the stock a "buy" rating in a research note on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, DexCom has a consensus rating of "Moderate Buy" and an average price target of $88.71.
Check Out Our Latest Research Report on DXCM
Hedge Funds Weigh In On DexCom
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB grew its stake in DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company's stock worth $77,000 after purchasing an additional 153 shares during the period. V Square Quantitative Management LLC lifted its stake in DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company's stock valued at $604,000 after buying an additional 172 shares during the period. Essex Financial Services Inc. lifted its stake in DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company's stock valued at $204,000 after buying an additional 175 shares during the period. Gabelli Funds LLC lifted its stake in DexCom by 0.4% in the fourth quarter. Gabelli Funds LLC now owns 50,200 shares of the medical device company's stock valued at $3,332,000 after buying an additional 200 shares during the period. Finally, One Wealth Map LLC boosted its holdings in shares of DexCom by 5.6% during the 1st quarter. One Wealth Map LLC now owns 4,900 shares of the medical device company's stock worth $301,000 after buying an additional 261 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.
DexCom Company Profile
(
Get Free Report)
DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.
The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
